Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 239
- Registration Number
- NCT01418989
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT01417377
- Locations
- 🇵🇰
Fatima Memorial Hospital; Nephrology, Lahore, Pakistan
🇵🇰Surgimed Hospital, Lahore, Pakistan
🇵🇰Sheikh Zayed Hospital; Department of Nephrology, Lahore, Pakistan
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy
Completed
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT01416610
- Locations
- 🇦🇹
Lkh-Univ. Klinikum Graz, Graz, Austria
🇦🇹Lkh Hoergas-Enzenbach; Abt. Für Innere Medizin, Gratwein, Austria
🇦🇹Lkh innsbruck - univ. Klinikum innsbruck - Tiroler landeskrankenanstalten ges.m.b.h.; Innere Medizin, Innsbruck, Austria
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Phase 3
Completed
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Interferon beta-1aDrug: OcrelizumabDrug: Ocrelizumab-matching placeboDrug: Interferon beta-1a-matching placebo
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 835
- Registration Number
- NCT01412333
- Locations
- 🇺🇸
Infinity Clinical Research, Hollywood, Florida, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Advanced Neurosciences Research LLC, Fort Collins, Colorado, United States
A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT01409369
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- Interventions
- Drug: HerceptinDevice: Single-Use Injection Device
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 488
- Registration Number
- NCT01401166
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 261
- Registration Number
- NCT01399697
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2011-07-21
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT01399190
A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01398293
A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT01398267
© Copyright 2025. All Rights Reserved by MedPath